Cushing Asset Management, LP Intra Cellular Therapies, Inc. Transaction History

Cushing Asset Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $10,363 - $15,819	-241 Reduced 1.79%	13,248 $756,000
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $3,060 - $4,905	-79 Reduced 0.58%	13,489 $825,000
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $208,665 - $316,673	5,928 Added 77.59%	13,568 $710,000
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $2,010 - $2,974	70 Added 0.92%	7,640 $285,000
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $19,308 - $29,325	-659 Reduced 8.01%	7,570 $309,000
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $57,164 - $73,330	1,856 Added 29.12%	8,229 $279,000
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $148,745 - $205,338	6,373 New	6,373 $203,000

387

85.9M

231K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Cushing Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cushing Asset Management, LP with notifications on news.